Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07302074

Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations and Immune Infiltrate Characterization : the UTOPIC Project

The pathophysiology of certain inflammatory arthritides remains poorly understood, particularly when associated with rare systemic autoimmune diseases such as systemic sclerosis (SSc), or when emerging in the context of immune-related adverse events from cancer immunotherapies. These immunotherapy-induced arthritides represent a new and increasingly encountered clinical entity in rheumatology. A deeper understanding of the mechanisms underlying joint inflammation in these settings is essential for identifying specific therapeutic targets, especially given the limitations of current treatment options and the risks associated with broad immunosuppressive strategies such as prolonged corticosteroid use, which may impair anti-tumor immune responses.

Synovial biopsy analysis provides a powerful tool for dissecting the cellular and molecular components of joint inflammation, including immune cell infiltration, cytokine profiles, and cell-cell interactions. Advances in high-dimensional techniques such as multiplex immunofluorescence and mass cytometry now allow for the identification and spatial localization of numerous protein markers at the subcellular level. Additionally, spatial transcriptomics offers complementary insight into gene expression profiles within the tissue microenvironment, providing a comprehensive understanding of inflammatory processes.

The investigators propose a prospective, proof-of-concept study to characterize and compare rare and emerging inflammatory arthritides-including those linked to SSc and immunotherapy-related immune toxicity-with classical inflammatory rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), spondyloarthritis (SpA), polymyalgia rheumatica (PMR), and reactive arthritis. Through detailed immunological and molecular profiling, this study aims to identify disease-specific signatures and novel therapeutic targets. These findings could pave the way for precision medicine approaches and inform the development of targeted therapies in both rare and common forms of inflammatory arthritis.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Inflammatory Arthritis Arthritis Connective Tissue Diseases Immune Checkpoint Inhibitor Related Inflamamtory Arthritis Joint Diseases Musculoskeletal Diseases Rare Auto-immune Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU bordeaux, Bordeaux, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • For all participants:
  • Signed consent form
  • Patients over 18 years old
  • Affiliated with a social security scheme
  • For cases:
  • Referred for arthritis or bursitis occurring in the context of a rare systemic autoimmune disease (SAID) or drug-induced toxicity.
  • Presenting at least one clinical arthritis with synovial thickening confirmed by ultrasound (grade ≥2 in B-mode) and Doppler inflammation of grade ≥1, or synovial thickening ≥B2 associated with joint effusion.

For bursitis: thickening ≥2mm of at least one periarticular bursa on ultrasound associated with Doppler inflammation of grade ≥1, or synovial thickening ≥2mm associated with joint effusion, with clinical evidence of inflammatory involvement.

*For the control group:

For arthritis:

  • Presenting clinical arthritis with synovial thickening confirmed by ultrasound (grade ≥2 in B-mode (B2)) and Doppler inflammation of grade ≥1, or synovial thickening ≥B2 associated with joint effusion.
  • Diagnosed, according to disease-specific classification criteria, with either rheumatoid arthritis (according to ACR/EULAR 2010 criteria), axial or peripheral spondyloarthritis (according to ASAS 2009 criteria), psoriatic arthritis (according to CASPAR criteria), or reactive arthritis based on clinician assessment.

For bursitis:

  • Thickening ≥2mm of at least one periarticular bursa on ultrasound associated with Doppler inflammation of grade ≥1, or synovial thickening ≥2mm associated with joint effusion.
  • Meeting the ACR/EULAR 2012 criteria for polymyalgia rheumatica.

Exclusion criteria

  • For all participants:
  • Patients under protective measures or unable to consent
  • Pregnant or breastfeeding women
  • Anticoagulant treatment: vitamin K antagonists (Coumadin, fluindione), direct oral anticoagulants (Eliquis, Pradaxa, Rivaroxaban), heparins at curative doses
  • Contraindication to local procedure: lymphedema near the joint, chronic wound at the site of the joint, joint prosthesis on the affected joint, corticosteroid infiltration less than 3 months ago at the same site
  • History of treatment with biotherapy or targeted therapy (JAK inhibitors) within the last 3 months, or within the last 6 months if treated with Rituximab

Treatment and study plan

Biopsy

Procedure

"A synovial biopsy will be carried out as recommended

Primary outcomes

  1. characterize the inflammatory infiltrate in synovial biopsies

    Time frame: Day 1

    Establishment of a biobank to characterize the inflammatory infiltrate in synovial biopsies from arthritis or bursitis occurring in the context of rare systemic autoimmune diseases (SAIDs) or immune-mediated drug toxicities, and to compare it with the infiltrate in the synovium of arthritis/bursitis associated with common inflammatory rheumatic conditions frequently encountered in rheumatology.

Secondary outcomes

  1. Study of the cytokine environment

    Time frame: day 1

    Study of the cytokine environment within synovial biopsies from arthritis/bursitis occurring in the context of rare autoimmune/inflammatory syndromes or drug toxicity

  2. Study of the cytokine environment

    Time frame: day 1

    Study of the cytokine environment within synovial biopsies fromarthritis/bursitis arising in common inflammatory rheumatic diseases.

  3. comparison of the cytokine environment

    Time frame: day 1

    comparison cytokine environment within synovial biopsies from arthritis/bursitis occurring in the context of rare autoimmune/inflammatory syndromes or drug toxicity, n with that of arthritis/bursitis arising in common inflammatory rheumatic diseases.

  4. Study of the gene expression profile of immune cells

    Time frame: day 1

    Study of the gene expression profile of immune cells present within synovial biopsies from arthritis/bursitis occurring in the context of rare autoimmune/inflammatory syndromes or drug toxicity,

  5. Study of the gene expression profile of immune cells

    Time frame: day 1

    Study of the gene expression profile of immune cells present that of arthritis/bursitis occurring in common inflammatory rheumatic diseases."

  6. comparison of the gene expression profile of immune cells

    Time frame: day 1

    comparison of the gene expression profile of immune cells in synovial biopsies from arthritis/bursitis occurring in the context of rare autoimmune/inflammatory syndromes or drug toxicity versus those from arthritis/bursitis occurring in common inflammatory rheumatic diseases

Study contacts

Contact information is provided by the study sponsor or research team.

Alice Tison, Dr

CONTACT

[email protected]

+33(0)298347264

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Collaborators

  • University Hospital, Bordeaux

Registry information

Acronym: UTOPIC

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Dec 24, 2025
Registry last updated
Apr 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.